POSTER SESSION 18 November 2022: Basic Science and Translational Research| Volume 175, SUPPLEMENT 1, S80, November 2022

Development of a multiplex dPCR assay for ERBB2 amplification in breast cancer

      Background: ERBB2 amplification on chromosome 17 serves as a marker for monoclonal antibodies targeting HER2 in cancers, most notably in breast cancer. Although immunohistochemistry (IHC) and in situ hybridization (FISH/SISH/CISH) remain the gold standard for clinical diagnosis of ERBB2 amplification, their semiquantitative and subjective nature are limitations that warrant the exploration of alternative quantitative, reliable, rapid, and cost-effective complementary approaches such as digital PCR (dPCR). Here we describe initial results with a dPCR-based SAGAplex™ assay for ERBB2 amplification.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect